0000000000770786

AUTHOR

Francesco Del Giudice

showing 3 related works from this author

How Can the COVID-19 Pandemic Lead to Positive Changes in Urology Residency?

2020

The COVID-19 outbreak, in a few weeks, overloaded Italian hospitals, and the majority of medical procedures were postponed. During the pandemic, with hospital reorganization, clinical and learning activities performed by residents suffered a forced remodulation. The objective of this study is to investigate how urology training in Italy has been affected during the COVID-19 era. In this multi-academic study, we compared residents' training during the highest outbreak level with their previous activity. Overall 387 (67.1%) of the 577 Italian Urology residents participated in a 72-h anonymous online survey with 36 items sent via email. The main outcomes were clinical/surgical activities, soci…

Telemedicinemedicine.medical_specialtyMultivariate analysisCoronavirus disease 2019 (COVID-19)Distance teachingDistance educationeducation030232 urology & nephrologyUrologylcsh:Surgery03 medical and health sciences0302 clinical medicineCOVID-19; pandemic; residency; residents; urologyMultidisciplinary approachPandemicMedicineresidenturologyOriginal ResearchSettore MED/24 - UROLOGIAbusiness.industrySocial distancepandemicCOVID-19lcsh:RD1-811Settore MED/24030220 oncology & carcinogenesisresidentsSurgeryurology; residency; residents; pandemic; COVID-19businessresidency
researchProduct

A prospective observational study on oral administration of Ellagic Acid and Annona Muricata in patients affected by non-muscle invasive bladder canc…

2021

Introduction: BCG and MMC shortage and Covid-19 pandemic, more recently, limit accessibility to maintenance regimen in intravesical prophylaxis against recurrence of non-muscle invasive bladder cancer (NMIBC). Ellagic acid (EA) and Annona muricata (AM) exert antitumor activity against different human tumours. An observational prospective study on the prophylactic effect of oral administration of EA+AM in patients avoiding maintenance regimen is presented. Materials and methods: Patients affected by NMIBC and not undergoing maintenance after a 6-week course of intravesical prophylaxis with MMC or BCG were entered. Tis and very high-risk tumours were excluded. After informed consent, the pati…

bladder carcinomamedicine.medical_specialtybacillus calmette-guerinmedicine.medical_treatment030232 urology & nephrologyAdministration Oralnutraceuticsintravesical instillationGastroenterologyAnnonalaw.inventionannona muricata03 medical and health sciences0302 clinical medicineAdjuvants ImmunologicRandomized controlled trialellagic acidOral administrationlawInternal medicineCytologymedicineHumansNeoplasm InvasivenessProspective StudiesProspective cohort studyPandemicsChemotherapyBladder cancermedicine.diagnostic_testSARS-CoV-2business.industryCOVID-19General MedicineCystoscopymedicine.diseaseRegimenAdministration IntravesicalUrinary Bladder Neoplasms030220 oncology & carcinogenesisBCG VaccineNeoplasm Recurrence Localbusinessannona muricata; bacillus calmette-guerin; bladder carcinoma; ellagic acid; intravesical instillation; nutraceuticsUrologia Journal
researchProduct

Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral…

2020

Objectives: The aim of this multicenter study was to investigate the prognostic role of type 2 diabetes mellitus (T2DM) comorbidity in a large multi-institutional cohort of patients with primary T1HG/G3 non–muscle-invasive bladder cancer (NMIBC) treated with transurethral resection of the bladder (TURB). Materials and methods: A total of 1,172 patients with primary T1 HG/G3 who had NMIBC on re-TURB and who received adjuvant intravesical bacillus Calmette-Guérin therapy with maintenance were included. Endpoints were recurrence-free survival and progression-free survival. Results: A total of 231 (19.7%) of patients had T2DM prior to TURB. Five-year recurrence-free survival estimates were 12.5…

Malemedicine.medical_specialtyDiabetes mellituUrologymedicine.medical_treatment030232 urology & nephrologyUrologyCystectomyResection03 medical and health sciences0302 clinical medicineDiabetes mellitusHigh gradeAdjuvants ImmunologicUrethraRecurrenceDiabetes mellitusmedicineHumansIn patientNeoplasm InvasivenessAgedNeoplasm StagingRetrospective StudiesBladder cancerProgressionbusiness.industryHigh riskBladder cancerType 2 Diabetes MellitusMiddle Agedmedicine.diseasePrognosisComorbidityProgression-Free Survival3. Good healthBladder cancer; Diabetes mellitus; High grade; High risk; Progression; RecurrenceSettore MED/24OncologyDiabetes Mellitus Type 2Urinary Bladder NeoplasmsChemotherapy Adjuvant030220 oncology & carcinogenesisCohortBCG VaccineFemaleNeoplasm GradingbusinessAdjuvantUrologic oncology
researchProduct